Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 1-Year High – Time to Buy?

Posted by Brenda Bartman on Jul 30th, 2026

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $18.59 and last traded at $18.2630, with a volume of 47660 shares. The stock had previously closed at $18.09.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on AMRX shares. Barclays upped their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 20th. Wall Street Zen upgraded Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, July 12th. UBS Group upped their target price on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Weiss Ratings cut Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Finally, Zacks Research downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Five equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.60.

Read Our Latest Report on Amneal Pharmaceuticals

Amneal Pharmaceuticals Stock Up 1.8%

The company has a 50 day simple moving average of $15.99 and a 200-day simple moving average of $14.19. The stock has a market cap of $6.09 billion, a price-to-earnings ratio of 50.26 and a beta of 1.26.

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $0.27 EPS for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million for the quarter. On average, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of Amneal Pharmaceuticals stock in a transaction on Monday, May 11th. The shares were sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the transaction, the director owned 93,660 shares of the company’s stock, valued at $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 17.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Kemnay Advisory Services Inc. bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $26,000. Federated Hermes Inc. increased its stake in Amneal Pharmaceuticals by 1,680.6% during the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock valued at $29,000 after buying an additional 2,168 shares during the period. Comerica Bank increased its stake in shares of Amneal Pharmaceuticals by 186.7% during the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after acquiring an additional 1,957 shares during the period. Spire Wealth Management raised its stake in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after buying an additional 1,023 shares in the last quarter. Finally, Transamerica Financial Advisors LLC raised its position in Amneal Pharmaceuticals by 541.9% in the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after acquiring an additional 2,460 shares in the last quarter. Institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.